Xanthine is one of the naturally occurring compounds in muscle tissue, liver spleen, pancreas, and other organs. It is also found in urine in the course of degradation of adenosine monophosphate (AMP) to uric acid. Methylated derivatives of the xanthine family are called methylxanthaines. These are either delivered naturally or artificially via agents such as caffeine, theophylline, aminophylline, and theobromine. Aminophylline is administered orally or intravenously. Aminophylline drug combination includes ethylenediamine and theophylline, usually in the ratio of 2:1. At this ratio, ethylenediamine increases solubility and aminophylline is generally found as a dihydrat. These are also called bronchodilators and are primarily used in the treatment of respiratory disorders such as asthma, chronic bronchitis, and chronic obstructive pulmonary disorder (COPD). These are muscle relaxants which help to improve contraction of diaphragm, protect the airways from irritants along with anti-inflammatory actions by calming lung muscles. The mechanism of action of aminophylline is not completely known. However, the 2012 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report revealed that these act as a phosphodiesterase inhibitors, adenosine receptor blockers, and histone deacetylase activators.
Factors such as increase in incidence of respiratory disorders due to pollution across the globe and rise in demand for cost effective treatment options drive the global aminophylline market. Technological advancements and rapid innovation in drug development specifically in the field of personalized medicine present significant opportunities to manufacturers in the global aminophylline market. However, launch of newer products, quality of the products, and severe side effects associated with the therapies are anticipated to hamper the growth of the global aminophylline market.
The global aminophylline market can be segmented based on disease indication, end-user, and region. In terms of disease indication, the market can be classified into chronic obstructive pulmonary disease (COPD), asthma, and infant apnea. The COPD segment is projected to dominate the market during the forecast period due to rise in prevalence of respiratory disorders and infections across the globe. Other factor likely to drive the segment is higher affordability of methylxanthines in the next few years. Based on end-user, the global aminophylline market can be categorized into hospitals, clinics, and ambulatory surgical centers. The hospitals segment is anticipated to dominate the market from 2018 to 2026 due to acceptance of new technologies and availability of high number of generic drugs for the treatment of asthma and other respiratory disorders.
The global aminophylline market can be segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to dominate the global market during the forecast period due to rise in prevalence of lung diseases, introduction of newer drugs, technological advancements, and rise in health care expenditure. According to the Centers for Disease Control and Prevention, chronic obstructive pulmonary disease (COPD) and acute lung injury are the leading causes of death in the U.S. Additionally, according to the American Lung Association, thousands of deaths were reported due to COPD in 2010. Europe is anticipated to be the second largest aminophylline market for aminophylline due to increase in incidence of respiratory diseases, rise in geriatric population, and presence of key players in the market. Introduction of novel generic drugs with greater effectiveness and lesser side effects are expected to hamper the growth of the aminophylline market in the region in the near future. The aminophylline market in Asia Pacific is likely to grow at a rapid pace due to increase in geriatric population with respiratory disorders, rise in disposable income, and government initiatives in health care.
Major players in the global aminophylline market include Altor BioScience Corporation, Ono Pharmaceutical Corporation Ltd., GlaxoSmithKline plc, and Octapharma AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.